Contract-Resource-Outsourcing-IndustryNews

51. New Data For GlaxoSmithKline's Vaccine, Cervarix, Presented At IPV Conference 5/12/2009
    Results from the first, large-scale comparative trial between licensed human papillomavirus (HPV) vaccines show that Cervarix generated a significantly higher immune response compared to Gardasil. The comparative study looked at two key measures of immune response, neutralising antibodies and memory B cells.
52. Important New Treatment Option Approved In US For Patients With The Most Aggressive Form Of Brain Cancer 5/11/2009
    Roche recently announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) for people with glioblastoma with progressive disease following prior therapy.
53. Moving Promising Drug Candidates To Clinical Trials Faster And More Reliably 5/7/2009
    Symyx Technologies, Inc. has announced the launch of the Symyx Contract Development and Manufacturing Organisation (CDMO).
54. New Data Presented At American Academy Of Neurology Congress Show 80-83% Of MS Patients On Oral FTY720 Were Relapse-Free For One Year - Significantly Better Than A Leading Current Treatment 4/30/2009
    New Phase III results presented at the American Academy of Neurology (AAN) congress show that 80-83% of patients taking FTY720 (fingolimod), an investigational oral compound for relapsing-remitting multiple sclerosis, remained free of relapses during the one-year study compared to 69% of those on interferon beta-1a, an established standard of care (p<0.001).
55. Bayer And Ardea Biosciences Enter Global Agreement Focused On The Development Of MEK Inhibitors For The Treatment Of Cancer 4/30/2009
    Bayer HealthCare AG, Germany has entered into a global agreement with Ardea Biosciences, Inc., San Diego California, USA focused on the development of small molecule mitogen-activated ERK kinase (MEK) inhibitors for the treatment of solid tumors.
56. Countries Unite To Reduce Animal Use In Product Toxicity Testing Worldwide U.S., Canada, Japan And European Union Sign International Agreement 4/28/2009
    Representatives from four international agencies, including the director of the U.S. National Toxicology Program (NTP), recently signed a memorandum of cooperation that could reduce the number of animals required for consumer product safety testing worldwide.
57. Galapagos Enters Strategic Alliance In Inflammatory Diseases With Merck & Co., Inc. 4/21/2009
    Galapagos NV announced recently that it has entered into a multi-year global strategic alliance with Merck & Co., Inc., through an affiliate, to develop potential new therapies in inflammatory diseases.
58. StemCells, Inc. Announces License Agreement With Major Pharmaceutical Company Covering Gene Insertion Technology 4/16/2009
    StemCells, Inc. announced today that a major international pharmaceutical company has taken a non-exclusive license to the Company’s recently acquired Internal Ribosome Entry Site (IRES) technology.
59. Increasing Small Molecule Biotech API Outsourcing Presents Challenges For CMC Management to Find Solutions 4/16/2009
    Gone are the days when the pharmaceutical scene was dominated only by "Big Pharma" and the blockbuster drugs it discovered.
60. Sanofi-Aventis To Acquire BiPar Sciences 4/16/2009
    Sanofi-aventis announced recently that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc., (“BiPar”) a privately held US biopharmaceutical company, developing novel tumor-selective approaches for the treatment of different types of cancers.